Corbus Pharmaceuticals Holdings, Inc.
$7.26
$0.00 (+0.00%)
$7.03Day Range$7.38
Key Statistics
Market Cap
$140.42M
Shares Outstanding
19.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 24, 2014
Round Lot
100
Locale
US
Trading Data
Day Open
$7.26
Day High
$7.38
Day Low
$7.03
Volume
992.9K
VWAP
$7.21
Prev Close
$7.26
Transactions
--
Acc. Volume
--
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
PHARMACEUTICAL PREPARATIONSSIC 283436 employees500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062617-963-0103IPO Oct 24, 2014US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001595097
- Composite FIGI
- BBG0078PJKQ7
- Share Class FIGI
- BBG0078PJKP8
- Ticker Root
- CRBP
- SIC Code
- 2834
About Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock
Corbus Pharmaceuticals Holdings, Inc. (CRBP) closed the 2026-09-17 session at $7.26, up 0.00% versus the previous close (+0.00). The stock opened at $7.26 and traded between $7.03 and $7.38 during that session. Session trading volume was 993K shares. The volume-weighted average price (VWAP) is $7.21.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Corbus Pharmaceuticals Holdings, Inc. has a market capitalization of $140.4 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. CRBP is listed on the XNAS exchange. The company employs approximately 36 people. Corbus Pharmaceuticals Holdings, Inc. is headquartered in NORWOOD, MA. The recorded listing date is 2014-10-24.
On this page you can find market CRBP stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.